Doses of ISIS 416858 an Antisense Inhibitor of Factor XI), Administered Subcutaneously to Patients with Renal Disease on Hemodialysis Frailty and the Dr. K. To determine if frailty 68 Transplant Tennankore, (using the Fried Frailty Waitlist Dr.Kiberd, Phenotype Assessment) is Dr. West, associated with a higher risk Dr. of death or permanent withdrawal from the Dr.Alwayn, transplant waitlist. Sills, etc FIDELIO-DKD Dr. K. Demonstrate whether, in 0 Industry (16244): A addition to standard of care randomised, (SoC),finerenone is superior double-blind, to placebo in delaying the West, progression of kidney controlled, Soroka) disease, as measured by the parallel-group, composite endpoint of time multicenter, to first occurrence of kidney event-driven failure, a sustained decrease phase III study to of eGFR 40% from ≥ investigate the baseline over at least 4 death efficacy and weeks or renal safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.
Doses of ISIS 416858 an Antisense Inhibitor of Factor XI), Administered Subcutaneously to Patients with Renal Disease on Hemodialysis Frailty and the Transplant Waitlist Dr. K. Tennankore, Dr.Kiberd, Dr. West, Dr. Dr.Alwayn, Sills, etc To determine if frailty (using the Fried Frailty Phenotype Assessment) is associated with a higher risk of death or permanent withdrawal from the transplant waitlist. 68 FIDELIO-DKD (16244): A randomised, double-blind, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease. Dr. K. West, Soroka) Demonstrate whether, in addition to standard of care (SoC),finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥ 40% from baseline over at least 4 death weeks or renal 0 Industry controlled,
renal-program-annual-report-20152016.docx